1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Cellid Co., Ltd.

Cellid Co., Ltd.

KKRX:299660
2,120.00
KRW
-55.00
(-2.53%)
-928.27EPS
41.48BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
81.78
43.09
- -
252.44
347.25
353.22
Basic EPS, GAAP
-276.91
-835.08
-1,243.89
-232.36
-373.87
-1,175.75
-2,052.77
-1,078
-743
-474
-928.27
Free Cash Flow per Basic Share
-254.73
-214.81
-860.93
-578.16
-1,402.51
-1,018.11
-1,204.75
-1,708.18
-1,741.3
-1,398.66
-936.49
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-21.9
-588.05
1,435.72
4,680.94
4,259.72
3,479.33
2,014.22
2,976.94
2,426.34
2,515.22
1,819.26
Tangible Book Value per Share
-33.45
-597.99
1,427.29
4,675.1
4,255.32
3,476.32
2,012.57
2,671.11
1,505.89
1,533.14
1,313.74
Basic Weighted Avg Shares
6
6
9
11
11
11
11
11
16
25
30
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
909
480
- -
4,165
8,842
10,420
Operating Margin (%)
- -
- -
- -
- -
- -
-1,431.2
-3,106.53
- -
-287.64
-128.29
-99.3
Depreciation Expense
65
70
77
110
492
2,288
2,600
2,664
2,734
2,515
2,047
Net Income, GAAP
-1,772
-5,408
-11,286
-2,494
-4,126
-13,071
-22,865
-11,611
-12,259
-12,069
-27,385
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-1,437.76
-4,763.45
- -
-294.33
-136.5
-262.8
Working Capital
3,238
559
7,860
26,441
11,931
18,962
439
6,549
6,507
-4,997
-15,228
LT Debt
- -
- -
- -
51
54
15,747
9
6,487
13,118
72
53
Total Equity
-206
-5,528
13,496
51,330
47,296
38,761
22,439
40,495
51,203
74,207
53,674
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-7.69
-8.37
-30.38
-74.72
-36.9
-26.74
-19.25
-40.66

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
27,706
29,460
33,689
LT Borrowings
- -
- -
- -
LT Finance Leases
72
63
53
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
84,379
72,872
41,481

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
24,429
22,976
20,599
Cash, Cash Equivalents & STI
22,400
19,454
16,897
Accounts Receivable, Net
310
241
216
Inventories
198
1,013
1,277
Total Current Liabilities
29,426
34,915
35,827
Payables & Accruals
- -
- -
- -
ST Debt
27,706
29,460
33,689
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
18.34%
44.93%
Free Cash Flow
- -
21.78%
23.96%
Net Income, GAAP
- -
49.3%
-1.55%
Sales/Revenue/Turnover
- -
- -
112.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
315
599
1,369
1,882
4,165
2025
1,573
2,129
2,333
2,807
8,842
2026
3,215
2,066
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-241.94
-192
-157
-169.91
-743
2025
-127.06
-116
-80.46
-152.65
-474
2026
-50.27
-645
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chang-Yul Kang
Full Time Employees
49
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building 142, Korea Seoul National University Seoul SL South Korea 08826
IPO Date
Feb 20, 2019
Website
cellid.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Cellid Co., Ltd. (299660.KQ) develops immunotherapeutic vaccines for cancer and infectious diseases using its proprietary CeliVax technology platform; core pipeline products include BVAC-C targeting HPV-related cancers such as cervical, head and neck, anal, and sex organ cancers via HPV E6/E7 antigens in phase II/III clinical trials, BVAC-B for HER-2/neu-positive stomach, breast, and ovarian cancers, BVAC-P for prostate, renal cell, and glioblastoma cancers using PAP/PSMA antigens advancing toward phase I trials, BVAC-M for melanoma with GP100/MAGE-A3 fusion antigens, and BVAC-Neo as a neoantigen-customized vaccine; the company also offers AdCLD-CoV19 COVID-19 vaccine in phase III and CDMO services leveraging GMP facilities for cell-based therapies. Founded in 2006 and headquartered at 142 dong, Seoul National University, Gwanak-gu, Seoul, South Korea, Cellid operates primarily in the biotechnology sector focusing on oncology and virology segments with global clinical trial reach. Recent developments include a newly launched CDMO service page highlighting integrated GMP production capabilities, addition to the S&P Global BMI Index in June 2024, and plans to raise KRW24 billion via share sale in March 2025 to support pipeline advancement and operations.